Kornimate/medical-research-clean huggingface dataset:
early prediction of fluoxetine response

Conditions: Major Depressive Disorder

Summary: the purpose of this study is to identify what degree of symptom changes during the early weeks could be used to predict eventual nonresponse at week 6 among depressive inpatients taking fluoxetine.

patients with major depressive disorder will receive 20 mg/day of fluoxetine for six weeks. symptom severity was assessed by the 17-item hamilton depression rating scale (hamd-17) at weeks 0, 1, 2, 3, 4 and 6. stable response is defined as a reduction of 50% or more of the hamd-17 score at week 4 and week 6 of treatment. receiver operating characteristic curve will be used to determine the cutoff point of the percentage of hamd-17 score reduction between stable responders and nonresponders at weeks 1, 2, 3 and 4.

Eligibility criteria:
inclusion criteria: * diagnosis of major depressive disorder * ham-d-17 ≧17 * written informed consent exclusion criteria: * comorbid of substance abuse/dependence * comorbid with mental disorders due to general medical conditions * past history of treatment-resistant depression * severe physical problems * pregnant women * lactation

Keywords: major depressive disorder, fluoxetine, hamilton rating scale for depression (ham-d-17)
establishment of social skills training group in adults with autism spectrum disorder and effectiveness analysis

Conditions: Social Skill Training Group

Summary: this project aims to examine the effectiveness of social skill training group in adults with autism spectrum disorders.


Eligibility criteria:
inclusion criteria: * age from 18 to 45 years * having relational problems * having motivation to participate * good chinese speaking * having a healthy cargiver join together * iq \> 70 (wais) * autism spectrum quotient \> 26 exclusion criteria: * ever had psychosis and neurological diseases * visual and hiring impairment
tcm in the treatment of lung adenocarcinoma

Conditions: Lung Adenocarcinoma

Summary: this study is to evaluate the efficacy and safety of jin-yuan-kang granule in the treatment of lung adenocarcinoma (luad) preliminarily, and provide reference for further study.

lung adenocarcinoma (luad) is a type of non-small cell lung cancer (nsclc) with a rapid disease progression and poor treatment effect. the luad patients have a short median survival time with 8-11 months. up to now, chemotherapy is still the first-line treatment for luad. pc protocol (pemetrexed + cisplatin) is most commonly used, which is also recommended by nccn guidelines. however, critical side effects have limited the application and efficacy. patients will undergo poor quality of life, and the disease will progress rapidly. we still face the stern situation for the treatment of luad. it is urgent to develop new treatment and management strategies. our previous study showed that jing-yuan-kang granule has certain curative effect on luad. this is a multi-certers, randomized, controlled clinical trial to assess the efficacy and safety of jing-yuan-kang granule in improving quality of life for luad patients. after a 2-week wash-out period, a total of 144 luad patients will be randomly assigned into experimental or control group with a ratio of 1:1. on the basis of that all the participants will receive pc chemotherapy and symptomatic treatment, the patients in the experimental group will receive jing-yuan-kang granule with no other treatments for control group. the primary outcome is quality of life. the secondary outcomes include karnofsky (kps) scores, clinical symptoms, and change of tumor volume. safety and adverse events will also be assessed.

Eligibility criteria:
inclusion criteria: * a confirmed diagnosis of ladc. * age ranges from17years to75years. * a kps score ≥40. * without radiotherapy, immunotherapy and targeted therapy. * without participanting in any other trial. * with signed informed consent. exclusion criteria: * pregnant, nursing or may become pregnant women. * the patient has a history of allergy to any of the components of the intervention drug; * patients with severe liver and kidney dysfunction, cardiovascular and cerebrovascular diseases. * unconscious or unable to communicate normally. * patients with poor compliance.
family icu delirium detection study

Conditions: Delirium

Summary: to evaluate the validity, reliability, and acceptability of employing family-administered delirium detection tools in the critically ill. the ultimate goal of this project is to improve the care of critically ill patients by creating valid, earlier, and patient and family-centered prevention, recognition, and management of delirium.

delirium is a major problem in critically ill patients, affecting almost half of this population. delirium is associated with substantial persistent impaired cognition and psychiatric comorbidity, attributable mortality, and increased healthcare costs. family members of critically ill patients are also at risk for developing adverse consequences including anxiety and depression. one strategy that may help both patients and families is to engage family members in the detection of delirium. the facilitated sensemaking model (of family member/patient engagement in critical care) is the theoretical framework underpinning the proposed work. facilitated sensemaking engages families by providing opportunities to participate in communication, decision-making, and bedside care, with the understanding that a sense of purpose derived from active participation in care can serve as a protective mechanism to reduce stress-related complications among families of critically ill patients, known as post-intensive care syndrome-family. family delirium detection may result in earlier and more accurate recognition of delirium and meaningful family involvement, and therein the potential for better patient and family outcomes. family-administered tools to measure delirium exist, but they have not been explored in the intensive care unit (icu) context; the icu is unique in terms of the patient population served and the invasiveness of therapies employed. we propose to evaluate the validity and reliability of using family-administered tools to detect delirium in critically ill patients and to explore perceptions and experiences of family members' participation in the detection of delirium. aim 1: to assess the validity and reliability of the family confusion assessment method (fam-cam) and sour seven to detect delirium in critically ill patients (phase 1). aim 2: to explore stakeholder (former icu patients and family members, nurse, physician) perceptions and experiences of family-administered delirium detection in critically ill patients (phase 2).

Eligibility criteria:
inclusion criteria: * richmond agitation sedation scale (rass) ≥-3 * able to communicate with study team (understand english, no significant hearing impairment) * located in icu exclusion criteria: * significant primary direct brain injury with a glasgow coma score (gcs) of \<9
ticagrelor in post-transplant patients with pediatric hepatic artery thrombosis (hat)

Conditions: Hepatic Artery Thrombosis; Liver Transplant; Complications; Pediatric Disease

Summary: hepatic artery thrombosis (hat) represents a major cause of graft loss and mortality after pediatric liver transplantation. ticagrelor (a new reversible inhibitor of p2y12 receptor with faster onset of action and greater platelet inhibition) was used to treat patients with pediatric post-transplant hepatic artery thrombosis (hat) compared to low molecular weight heparin.

in pediatric patients with post-transplant hepatic artery thrombosis (hat) , low molecular weight heparin is a commonly used method. ticagrelor, a direct-acting and reversible adp receptor antagonist, is now the most commonly used adp receptor antagonist in the treatment of coronary diseases. compared to its predecessor clopidogrel, the pharmacokinetic profil of ticagrelor is more predictable, demonstrating a faster onset of action and a more consistent platelet inhibition. however, because of the excellent antithrombotic effect and increased bleeding potential, it is recommended that major bleeding, such as opcab or cabg surgery, be expected with a high probability, and in case of fatal surgery, the drug should be discontinued for 5 days. the present study is to evaluate the safety and efficacy of ticagrelor in pediatirc receipt with post-operative hat.

Eligibility criteria:
inclusion criteria: * age from 2 months to 5 years old. * voluntary participation in clinical trials, and informed consent; * contrast- enhanced ultrasonography proved hat exclusion criteria: * history of sensitivity to study medications or any of their excipients * renal failure (egfr \<30 or requiring dialysis) * a known bleeding diathesis, hemostatic or coagulation disorder, or prior major bleeding * prior stroke * active pathological bleeding * history of intracranial haemorrhage * life expectancy \<12 months based on investigator's judgement * patients considered to be at risk of bradycardic events (e.g., known sick sinus syndrome or second or third degree atrioventricular \[av)\] block) unless already treated with a permanent pacemaker * anemia (hematocrit \< 27%) * platelet count \< 100,000/ml * concomitant use of strong cyp 3a inhibitors or inducers
a study of ro6807952 in patients with diabetes mellitus type 2

Conditions: Diabetes Mellitus Type 2

Summary: this randomized, placebo-controlled, multiple ascending dose study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of ro6807952. patients will receive multiple weekly subcutaneous doses of ro6870952. the anticipated time on study treatment is 8 weeks.


Eligibility criteria:
inclusion criteria: * adult patients, 18 to 70 years of age, inclusive * diagnosis of type 2 diabetes \>/=3 months and \</=10 years prior to screening * fasting plasma glucose \>/=110 mg/dl and \</=240 mg/dl * patients on a stable dose of metformin for at least 2 months prior to screening * hemoglobin hba1c \>/=6.5% and \</=10.5% * body mass index \>/=25 kg/m2 and \</=42 kg/m2 * systolic blood pressure \<155 mmhg and diastolic blood pressure \<95 mmhg exclusion criteria: * patients with type 1 diabetes * history of significant renal and hepatic diseases * history of metabolic acidosis and diabetic gastroparesis * history of pancreatitis * history of coagulation disorders or unexplained excessive bleeding * history of clinically significant cardiovascular disease or severe symptomatic hypoglycemia within 6 months of screening
tobacco and alcohol influence on oncogenic drivers and somatic evolution in the oral mucosa

Conditions: Carcinoma, Squamous Cell

Summary: head and neck cancers represent more than 500,000 cases per year worldwide, and often involve post-treatment relapse. the oral cavity is the most frequent site, but early disease stages are still insufficiently characterised and poorly detected. the study's aim is to better understand the oral mucosa somatic evolution, and how it can give rise to oral squamous cell carcinoma (oscc). this is a multi-centric, descriptive, non-interventional cohort in healthy adult subjects. the aim of the study is to detect the presence of oscc driver gene mutations in healthy subjects' oral mucosa, quantify whether they provide cells with a selective advantage, and study the impact of tobacco and alcohol consumption on the mutational load. this study will not allow to identify potential malignant cells, and will be usable for diagnostic purposes.


Eligibility criteria:
inclusion criteria: * man or woman aged 18 or more. * subject coming to odontology practice for routine visit. * subject having accepted to participate to the research by oral non-opposition * subject having given additional written consent for genetic studies. * smoking group criterion: subjects having smoked 100+ cigarettes/joints during their life. exclusion criteria: * personal history of cancer, whichever the type. * treatment with anticoagulants or platelet aggregation inhibitors. * bilateral lesions of the inner cheek preventing painless biological sample collection. * subject under under guardians or curators * pregnancy or breastfeeding * cannabis usage

Keywords: oral cytobrush healthy oral mucosa oral squamous cell carcinoma tobacco and alcohol
fragmentation of elastin as a biological marker of frailty and impact in tumor progression in elderly patients with cancer

Conditions: Cancer

Summary: the aim of the study is to evaluate frailty in patients aged ≥ 65 years with cancer. the elderly population is very heterogeneous, it is necessary to evaluate these elderly patients before treatment to assess the risk-benefit balance. to date, this assessment relies on subjective clinical methods often not optimal, and slow to implement. an innovative method of evaluation could be the determination of elastin peptides. indeed, the rate of these peptides, which are linked to serious conditions associated with age, rising inexorably with age and dose could help determine more objectively the type of treatment to offer older patients. expected results : this study will allow better identification of the group of frail elderly through more relevant biological marker that clinical assessment, often subjective and not available within a period compatible with the treatment of newly diagnosed cancer. this biological assessment will also enable optimal management of elderly patients in particular by allowing the geriatrician better efficiency.


Eligibility criteria:
inclusion criteria: * 65 years or older * diagnosis of cancer * affiliation to a social security scheme * signed informed consent for the study and for the collection of biological samples exclusion criteria: * patient protected by law (guardianship, trusteeship)
study comparing esomeprazole and asa combined together as one capsule versus these medications taken separately

Conditions: Peptic Ulcer Disease

Summary: the purpose of this study is to investigate whether a fixed dose combination (fdc) capsule of esomeprazole 20 mg and acetylsalicylic acid (asa) 81 mg has equivalent therapeutic efficacy compared to each of 2 free combinations of asa tablet 81 mg plus esomeprazole 20 mg in patients at risk of gastrointestinal events using low dose asa for cardiovascular protection.


Eligibility criteria:
inclusion criteria: * non-smoking male and female subjects, aged 18 years or older with a documented history of uncomplicated peptic ulcer(s), or aged 65 years or older * body mass index (bmi = weight/height2) greater than or equal to 18.5 kg/m2 and less than or equal to 35.0 kg/m2 exclusion criteria: * known history of hypersensitivity to esomeprazole (e.g. nexium®) or related drugs such as omeprazole (e.g. losec®, prilosec®), lansoprazole (e.g. prevacid®, hp-pac®), pantoprazole (e.g. pantoloc®, panto® iv), or rabeprazole (e.g. pariet™), a known hypersensitivity to asa (e.g. aspirin®) and/or related drugs such as ibuprofen (e.g. motrin®, advil®), indomethacin (e.g. indocin®), diclofenac (e.g. voltaren®), naproxen (e.g. aleve®, naprosyn®), or ketoprofen (e.g. rhovail®). * significant history of pulmonary, endocrine, musculoskeletal, neurological, hematological, liver or kidney disease, or gastrointestinal disease (with the exception of uncomplicated peptic ulcer), unless deemed ncs by the principal investigator or sub-investigator

Keywords: bioequivalence asa esomeprazole peptic ulcer disease ph measurements
comparative study of the magnetic-controlled capsule endoscopy versus standard gastroscopy

Conditions: Gastric Symptoms; Indicated for Upper GI Endoscopy

Summary: passive video capsule endoscopy is the criterion standard for small-bowel diseases but cannot be used for the large gastric cavity.this blinded prospective study investigates the accuracy of the magnetic-controlled capsule endoscopy compared to gastroscopy in patients with gastric symptoms and indication for upper gi endoscopy.


Eligibility criteria:
inclusion criteria: * patients with gastric symptoms and indicated for upper gi endoscopy * age of 18 years to 70 years exclusion criteria: * patients with impaired bowel movement from ileus or organic digestive diseases * patients with known large and obstructing tumors of the upper gi tract * patients after upper gi surgery or abdominal surgery altering gi anatomy * patients under full anticoagulation * patient in poor general condition * patients using equipment that may be affected by radio transmission * patients using equipment that may be affected by magnetic field * pregnancy or suspected pregnancy
encouraging allergic young adults to carry epinephrine

Conditions: Adherence; Food Allergy

Summary: fifteen million americans suffer from food allergies. food allergies can be life threatening; the only known life-saving treatment is epinephrine. adolescents/young adults are at increased risk of adverse events, because of increased risk-taking with food and decreased likelihood of carrying epinephrine. this is a pilot randomized trial to test text message reminders, with and without financial incentives, to encourage allergic young adults to carry epinephrine.

aim: we pilot tested a novel strategy to encourage young adults with food allergies to carry their epinephrine auto-injectors. adolescents/young adults are at increased risk of adverse events, because of increased risk-taking with food and decreased likelihood of carrying epinephrine. study design: this is a pilot randomized controlled trial, with a survey component. text messaging is the mode of communication and inquiry with study participants. hypothesis: the intervention group, which will receive modest financial incentives for carrying epinephrine, will be more likely to demonstrate that they are carrying their epinephrine, when queried by the study team. this study employs text messaging, along with photography, as a mode of momentary ecologic assessment, or real-time measurement of epinephrine carrying. in addition, text messaging was used as a mode of asking questions regarding food allergy knowledge and beliefs among young adults. text messages were sent from a designated telephone (and telephone number) purchased for use in this study. we used text messaging for reminder messages, text responses, and for the participants to send photographs back to us. we converted text message data (participants responses) into a redcap database. our research coordinator sent and received the text messages and compiled a secure redcap database of responses.

Eligibility criteria:
inclusion criteria: * have known food allergy * epinephrine auto-injector prescription * access to a cell phone with ability to send picture messages exclusion criteria: -
testing an integrated care model trial

Conditions: Diabetes Mellitus, Type 1

Summary: this study aims to test the use of an adapted collaborative care model for improving the health outcomes of adults diagnosed with type 1 diabetes (t1d). the duration of the study is 18 months with 4 study survey points. participants will fill out an online survey regarding their psychosocial health and chronic disease management behaviors once every six months over the 18 months, and individuals who are randomly assigned to the study intervention will also consult at least once with a behavioral health consultant during the first year (active intervention period).

type 1 diabetes (t1d) is a lifelong condition that requires consistent monitoring and management, increasing people's risk for common mental disorders that worsen diabetes self-care. both depression and diabetes can be managed with behavioral interventions, however, they are rarely provided alongside routine diabetes care for people with t1d. in this research study, the investigators aim to evaluate the implementation and effectiveness outcomes of a collaborative care model that uses a behavioral health consultant (bhc) to support lifestyle management among adults with t1d receiving diabetes care at the grady diabetes clinic. a trained clinical research coordinator will screen interested patients seeking treatment at the grady diabetes center and conduct outreach to individuals who have been identified as having t1d within the grady diabetes center's patient population. participants in the intervention group will engage with a behavioral health consultant (bhc) not affiliated with grady who will work with them to establish personalized health goals and identify ways to manage stress and promote healthy behaviors as means to support their mental and physical health and meet their set goals (i.e., behavioral activation). each session will be conducted over the telephone or zoom and last 30-60 minutes, with the number and frequency of meetings established through discussions between the patient and bhc (typically 2-3 sessions for one year). checklist and summary case reporting templates will be used to track intervention fidelity. the bhc will also participate in ongoing zoom calls with the multi-disciplinary t1d clinical team at the grady diabetes center once a month to provide updates on patients' behavioral health plans. transitioning patients from the active intervention will involve discussions with the care team to ensure continued patient support. in cases of active suicidal ideation, the study team will notify the patient's usual diabetes care provider and the individual will be referred to psychiatric services at grady.

Eligibility criteria:
inclusion criteria: * adults (≥18 years) with t1d (based on clinical record diagnosis). exclusion criteria: * patients who do not speak english or have reliable telephone access will be excluded. --- * individuals with the presence of severe psychiatric illness (phq-9≥20) or active suicidal ideation will also be excluded and referred to specialty care.

Keywords: behavioral health